Delving into the Latest Updates on IMA-970A with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Cancer Vaccine, HepaVac-101 vaccine, Hepatocellular carcinoma vaccine

+ [2]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Fondazione Irccs Istituto Nazionale Dei Tumori

Active Organization

CureVac SEUniversity Of InsurbiaFondazione Irccs Istituto Nazionale Dei Tumori

+ [2]

Inactive Organization

CureVac NV

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The trial is designed as a single-arm, open-label, phase I study investigating an off-the-shelf, multi-peptide-base HCC vaccine plus Montanide, combined with Durvalumab in patients with very early, early and intermediate stage of HCC. The investigational agents will be applied without concomitant anti-tumour therapy with the intention to reduce risk of recurrence/progression in patients who have received all indicated standard treatments.

Start Date22 Nov 2022

Sponsor / Collaborator

National Cancer Institute

NCT03203005

/ CompletedPhase 1/2IIT

A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments

This study is being carried out in order to evaluate a new cancer vaccine called IMA970A combined with CV8102, a new adjuvant for the treatment of liver cancer (hepatocellular carcinoma). It will be investigated whether IMA970A and CV8102 is safe and can trigger an immune response against the tumor, which may prevent the tumor (cancer) from recurring or spreading or may even lead to tumor shrinkage following the standard treatments the patients have previously received.

Start Date18 Sep 2017

Sponsor / Collaborator

National Cancer Institute

[+2]

JPRN-UMIN000004664

/ RecruitingPhase 1/2IIT

Cancer Vaccine Therapy using Gene of antigen related to new cancer origin Epitope Peptide Restricted to HLA-A24 in Patients with Hepatocellular carcinoma(Phase 1/2 study). - Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A24 in Patients with Hepatocellular carcinoma(Phase1/2 study).

Start Date01 Dec 2010

Sponsor / Collaborator-

100 Clinical Results associated with IMA-970A

Login to view more data

100 Translational Medicine associated with IMA-970A

Login to view more data

100 Patents (Medical) associated with IMA-970A

Login to view more data

240

Literatures (Medical) associated with IMA-970A

01 Dec 2025·Immunogenetics

VaxOptiML: leveraging machine learning for accurate prediction of MHC-I and II epitopes for optimized cancer immunotherapy

Article

Author: T, Dhanushkumar ; G, Sunila B ; Vasudevan, Karthick ; Selvam, Prasanna Kumar ; Hebbar, Sripad Rama

Cancer immunotherapy hinges on accurate epitope prediction for advancing vaccine development. VaxOptiML (available at https://vaxoptiml.streamlit.app/ ) is an integrated pipeline designed to enhance epitope prediction and prioritization. This study aims to develop and deploy a robust tool for accurate prediction and prioritization of highly immunogenic and optimized MHC-I and MHC-II T-cell epitopes for cancer vaccine development and immunotherapy. Utilizing a curated dataset of experimentally validated epitopes and employing sophisticated machine learning techniques, VaxOptiML features three models: epitope prediction from target sequences, personalized HLA typing, and prioritization the predicted epitopes based on immunogenicity scores. Our rigorous data extraction, cleaning, and feature extraction processes, coupled with model building, yield exceptional accuracy, sensitivity, specificity, and F1 score, surpassing existing prediction methods. Comprehensive visual representations underscore VaxOptiML's robustness and efficacy in accelerating epitope discovery and vaccine design for cancer immunotherapy. Deployed via Streamlit for public use, VaxOptiML enhances accessibility and usability for researchers and clinicians, demonstrating significant potential in cancer immunotherapy.

01 Jan 2025·Acta Biomaterialia

Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models

Article

Author: Xiao, Ze-Xiu ; Zha, Gao-Feng ; Zhang, Changhua ; Xu, Yuandong ; Shi, Guangzhao ; Qiu, Haowei ; Cao, Fei

While accessing tumor neoantigens and developing effective delivery systems have posed significant challenges in therapeutic oncology vaccines, this study introduces a cost- and time-efficient personalized tumor vaccine demonstrating potent anti-tumor effects in a mouse xenograft model. This vaccine utilizes a lipid nanoparticle (C5 LNP) system loaded with membrane protein antigens (mAg) derived from surgically excised tumor tissue. Its safety and efficacy were validated in a B16-OVA murine model. C5/OVA exhibited significant uptake by dendritic cells (DCs), leading to cross-presentation, maturation, and subsequent initiation of robust cell-mediated and humoral immune responses. This resulted in clear tumor growth suppression and extended survival in the B16-OVA model. Furthermore, the personalized C5/mAg vaccine effectively inhibited tumor growth in a colorectal carcinoma model. When combined with anti-PD-1 therapy, it notably increased complete remission (CR) rates in the CT26 xenograft model. Vaccinated mice demonstrated 100 % resistance to tumor rechallenge, underscoring the vaccine's ability to induce long-term immune memory. This study presents a promising personalized cancer vaccine delivery system with potential for both treatment and prevention of carcinoma in clinical applications. STATEMENT OF SIGNIFICANCE: In this paper, we present a scheme for manufacturing personalized tumor vaccines. The vaccine component consists of lipid nanoparticles (LNPs) designated C5 and membrane protein antigens (mAg) derived from autologous tumor tissue surgically resected from the patient. Our study demonstrates that the personalized mAg-C5 vaccine for colorectal carcinoma significantly inhibits tumor growth. Furthermore, conjugation with anti-PD-1 therapy demonstrably increased the complete remission (CR) rate in the murine CT26 xenograft tumor model. Additionally, mice treated with the C5/mAg vaccine exhibited 100 % resistance to tumor growth in a colon carcinoma rechallenge model, indicating the induction of immune memory by the vaccine. Our research results suggest that the mAg-LNP vaccine is a simple, cost-effective treatment that clinicians can easily and quickly integrate into routine practice.

16 Dec 2024·ACS Applied Bio Materials

Injectable and Degradable Zwitterionic Cryogels as Cancer Vaccine Platforms to Prevent Cancer Recurrence after Surgery

Article

Author: Zhang, Jing ; Mou, Xiaozhou ; Feng, Jie ; Ni, Haifeng ; Luo, Xinxin ; Lu, Jie

Cancer has become a highly prevalent disease and poses serious threats to human health. Conventional cancer treatments still face high risks of recurrence. Training the immune system to recognize and eliminate tumors via external stimulation, such as vaccines, emerges as a promising approach for cancer prevention and treatment. However, injectable vaccines may have limited immune activation, causing difficulties in maintaining long-term immune surveillance of tumorigenesis by tumor-specific cytotoxic T cells. Here, degradable zwitterionic cryogels were prepared using the cryogelation technique. The cryogenic preparation maintained the biological activities of tumor antigens and immune adjuvants loaded in the cryogels. The macroporous structure endowed the injectability of cryogels into the body via conventional syringes. In the presence of proteases, the cryogels degraded, allowing sustained release of antigens and adjuvants, ensuring continued dendritic cell (DC) recruitment and antigen presentation to maturing tumor-specific cytotoxic T cells. In vivo experiments demonstrated that the cryogel cancer vaccines elicited robust immune activation and effectively modulated tumor microenvironments. The combination with photothermal therapy significantly inhibited tumor growth, showing great potential for preventing postoperative recurrence. Additionally, the zwitterionic cryogels were biocompatible without obvious toxicities during degradation. The cryogels could serve as effective vaccine platforms to prevent cancer recurrence after surgery.

100 Deals associated with IMA-970A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 2	-	University Of Insurbia	-
Hepatocellular Carcinoma	Phase 2	-	Fondazione Irccs Istituto Nazionale Dei Tumori	-
Hepatocellular Carcinoma	Phase 2	-	Immatics Biotechnologies GmbH	-
Hepatocellular Carcinoma	Phase 2	-	CureVac SE	-
Hepatocellular Carcinoma	Phase 2	-	Universitaetsklinikum Tuebingen	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03203005 (Pubmed \| Clin Cancer Res) Manual	Phase 1/2	Hepatocellular Carcinoma	22	Cyclophosphamide+IMA 970 A+CV 8102	hhnuwcvjaq(wmlvuxbwtz) = against ≥1 vaccinated HLA class I tumor-associated peptide (TAA) and ≥1 vaccinated HLA class II TAA were respectively induced in 37% and 53% of the vaccinees qyippjxsnb (xtplkcuemr ) View more	Positive	13 Jun 2022